NEUROCRINE BIOSCIENCES, INC.
- Country
- πΈπͺSweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 1.4K
- Market Cap
- $15.4B
- Website
- http://www.neurocrine.com
Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 40
- Registration Number
- NCT03687684
- Locations
- π―π΅
Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
- Conditions
- Interventions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 14
- Registration Number
- NCT03562494
- Locations
- πΊπΈ
UC Irvine, Irvine, California, United States
πΊπΈUniversity of Philadelphia, Dept of Neurology, Philadelphia, Pennsylvania, United States
πΊπΈNorthwestern Medical Faculty Foundation, Chicago, Illinois, United States
Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 81
- Registration Number
- NCT03530293
- Locations
- πΊπΈ
Neuricrine Clinical Site, Sun City, Arizona, United States
π΅π·Neurocrine Clinical Site, San Juan, Puerto Rico
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 18
- Registration Number
- NCT03525886
- Locations
- πΊπΈ
Neurocrine Clinical Site, Seattle, Washington, United States
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 16
- Registration Number
- NCT03496870
- Locations
- πΊπΈ
Neurocrine Clinical Site, Farmington Hills, Michigan, United States
Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 85
- Registration Number
- NCT03444038
- Locations
- π΅π·
Neurocrine Clinical Site, San Juan, Puerto Rico
A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 256
- Registration Number
- NCT03382639
- Locations
- πΊπΈ
Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States
π΅π±NZOZ Poradnia Zdrowia Psychicznego, Kobierzyce, Poland
π΅π±Centrum Medyczne Plejady, Krakow, Poland
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 31
- Registration Number
- NCT03359785
- Locations
- πΊπΈ
CBH Health, LLC, Gaithersburg, Maryland, United States
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 127
- Registration Number
- NCT03325010
- Locations
- π΅π·
Neurocrine Clinical Site, San Juan, Puerto Rico
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 23
- Registration Number
- NCT03319953
- Locations
- π¬π§
Kings College London, London, United Kingdom